Tech Mahindra planning to start trials for COVID drug in next three to four months
11th Aug 2021

Tech Mahindra is planning to start trials for a COVID drug in the next three to four months after receiving the patent for a particular molecule. Markers Lab, the research and development arm of the IT company, is working on developing the drug. The company along with Reagene Biosciences has filed for a patent for a molecule that can be used to develop a drug against coronavirus.

Tech Mahindra represents the connected world, offering innovative and customer-centric information technology experiences, enabling Enterprises, Associates and the Society to Rise.